Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Wei Website

Jun S. Wei, Ph.D.

Selected Publications

1)  Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, Brohl AS, Sindiri S, Catchpoole D, Badgett T, Getz G, Mora J, Anderson JR, Skapek SX, Barr FG, Meyerson M, Hawkins DS, Khan J.
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.
Cancer Discov. 4: 216-31, 2014.
[Journal]
2)  Metaferia B, Wei JS, Song YK, Evangelista J, Aschenbach K, Johansson P, Wen X, Chen Q, Lee A, Hempel H, Gheeya JS, Getty S, Gomez R, Khan J.
Development of peptide nucleic acid probes for detection of the HER2 oncogene.
PLoS ONE. 8: e58870, 2013.
[Journal]
3)  Wei JS, Johansson P, Chen L, Song YK, Tolman C, Li S, Hurd L, Patidar R, Wen X, Badgett TC, Cheuk AT, Marshall JC, Steeg PS, Vaqué Díez JP, Yu Y, Gutkind JS, Khan J.
Massively parallel sequencing reveals an accumulation of de novo mutations and an activating mutation of LPAR1 in a patient with metastatic neuroblastoma.
PLoS ONE. 8: e77731, 2013.
[Journal]
4)  Li SQ, Cheuk AT, Shern JF, Song YK, Hurd L, Liao H, Wei JS, Khan J.
Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).
PLoS ONE. 8: e76551, 2013.
[Journal]
5)  Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, Kim J, Lawrence MS, Lichenstein L, McKenna A, Pedamallu CS, Ramos AH, Shefler E, Sivachenko A, Sougnez C, Stewart C, Ally A, Birol I, Chiu R, Corbett RD, Hirst M, Jackman SD, Kamoh B, Khodabakshi AH, Krzywinski M, Lo A, Moore RA, Mungall KL, Qian J, Tam A, Thiessen N, Zhao Y, Cole KA, Diamond M, Diskin SJ, Mosse YP, Wood AC, Ji L, Sposto R, Badgett T, London WB, Moyer Y, Gastier-Foster JM, Smith MA, Guidry Auvil JM, Gerhard DS, Hogarty MD, Jones SJ, Lander ES, Gabriel SB, Getz G, Seeger RC, Khan J, Marra MA, Meyerson M, Maris JM.
The genetic landscape of high-risk neuroblastoma.
Nat. Genet. 45: 279-84, 2013.
[Journal]
6)  Wang C, Liu Z, Woo CW, Li Z, Wang L, Wei JS, Marquez VE, Bates SE, Jin Q, Khan J, Ge K, Thiele CJ.
EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.
Cancer Res. 72: 315-24, 2012.
[Journal]
7)  Stauffer JK, Orentas RJ, Lincoln E, Khan T, Salcedo R, Hixon JA, Back TC, Wei JS, Patidar R, Song Y, Hurd L, Tsokos M, Lai EW, Eisenhofer G, Weiss W, Khan J, Wigginton JM.
High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery.
Cancer Invest. 30: 343-63, 2012.
[Journal]
8)  Orentas RJ, Yang JJ, Wen X, Wei JS, Mackall CL, Khan J.
Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers.
Front Oncol. 2: 194, 2012.
[Journal]
9)  Tsang PS, Cheuk AT, Chen QR, Song YK, Badgett TC, Wei JS, Khan J.
Synthetic lethal screen identifies NF-?B as a target for combination therapy with topotecan for patients with neuroblastoma.
BMC Cancer. 12: 101, 2012.
[Journal]
10)  Briggs JW, Ren L, Nguyen R, Chakrabarti K, Cassavaugh J, Rahim S, Bulut G, Zhou M, Veenstra TD, Chen Q, Wei JS, Khan J, Uren A, Khanna C.
The ezrin metastatic phenotype is associated with the initiation of protein translation.
Neoplasia. 14: 297-310, 2012.
[Journal]
11)  Chen QR, Yu LR, Tsang P, Wei JS, Song YK, Cheuk A, Chung JY, Hewitt SM, Veenstra TD, Khan J.
Systematic proteome analysis identifies transcription factor YY1 as a direct target of miR-34a.
J. Proteome Res. 10: 479-87, 2011.
[Journal]
12)  Gheeya J, Johansson P, Chen QR, Dexheimer T, Metaferia B, Song YK, Wei JS, He J, Pommier Y, Khan J.
Expression profiling identifies epoxy anthraquinone derivative as a DNA topoisomerase inhibitor.
Cancer Lett. 293: 124-31, 2010.
[Journal]
13)  Chen QR, Song YK, Yu LR, Wei JS, Chung JY, Hewitt SM, Veenstra TD, Khan J.
Global genomic and proteomic analysis identifies biological pathways related to high-risk neuroblastoma.
J. Proteome Res. 9: 373-82, 2010.
[Journal]
14)  Taylor JG, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, Yu Y, Chen QR, Shah K, Youngblood V, Fang J, Kim SY, Yeung C, Helman LJ, Mendoza A, Ngo V, Staudt LM, Wei JS, Khanna C, Catchpoole D, Qualman SJ, Hewitt SM, Merlino G, Chanock SJ, Khan J.
Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
J. Clin. Invest. 119: 3395-407, 2009.
[Journal]
15)  Wei JS, Johansson P, Chen QR, Song YK, Durinck S, Wen X, Cheuk AT, Smith MA, Houghton P, Morton C, Khan J.
microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies.
Clin. Cancer Res. 15: 5560-8, 2009.
[Journal]
16)  Gheeya JS, Chen QR, Benjamin CD, Cheuk AT, Tsang P, Chung JY, Metaferia BB, Badgett TC, Johansson P, Wei JS, Hewitt SM, Khan J.
Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma.
Cancer Biol. Ther. 8: 2386-95, 2009.
[Journal]
17)  Chen QR, Song YK, Wei JS, Bilke S, Asgharzadeh S, Seeger RC, Khan J.
An integrated cross-platform prognosis study on neuroblastoma patients.
Genomics. 92: 195-203, 2008.
[Journal]
18)  Wei JS, Badgett TC, Khan J.
New Technologies for Diagnosing Pediatric Tumors Expert Opinion on Medical Diagnostics.
Expert Opin Med Diagn. 2: 1205-1219, 2008.
[Journal]
19)  Wei JS, Song YK, Durinck S, Chen QR, Cheuk AT, Tsang P, Zhang Q, Thiele CJ, Slack A, Shohet J, Khan J.
The MYCN oncogene is a direct target of miR-34a.
Oncogene. 27: 5204-13, 2008.
[Journal]
20)  Bilke S, Chen QR, Wei JS, Khan J.
Whole chromosome alterations predict survival in high-risk neuroblastoma without MYCN amplification.
Clin. Cancer Res. 14: 5540-7, 2008.
[Journal]
21)  Whiteford CC, Bilke S, Greer BT, Chen Q, Braunschweig TA, Cenacchi N, Wei JS, Smith MA, Houghton P, Morton C, Reynolds CP, Lock R, Gorlick R, Khanna C, Thiele CJ, Takikita M, Catchpoole D, Hewitt SM, Khan J.
Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis.
Cancer Res. 67: 32-40, 2007.
[Journal]
22)  Chen QR, Vansant G, Oades K, Pickering M, Wei JS, Song YK, Monforte J, Khan J.
Diagnosis of the small round blue cell tumors using multiplex polymerase chain reaction.
J Mol Diagn. 9: 80-8, 2007.
[Journal]
23)  Westermann F, Henrich KO, Wei JS, Lutz W, Fischer M, König R, Wiedemeyer R, Ehemann V, Brors B, Ernestus K, Leuschner I, Benner A, Khan J, Schwab M.
High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.
Clin. Cancer Res. 13: 4695-703, 2007.
[Journal]
24)  Chen QR, Bilke S, Wei JS, Greer BT, Steinberg SM, Westermann F, Schwab M, Khan J.
Increased WSB1 copy number correlates with its over-expression which associates with increased survival in neuroblastoma.
Genes Chromosomes Cancer. 45: 856-62, 2006.
[Journal]
25)  Henrich KO, Fischer M, Mertens D, Benner A, Wiedemeyer R, Brors B, Oberthuer A, Berthold F, Wei JS, Khan J, Schwab M, Westermann F.
Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients.
Clin. Cancer Res. 12: 131-8, 2006.
[Journal]
26)  Krasnoselsky AL, Whiteford CC, Wei JS, Bilke S, Westermann F, Chen QR, Khan J.
Altered expression of cell cycle genes distinguishes aggressive neuroblastoma.
Oncogene. 24: 1533-41, 2005.
[Journal]
27)  Wei JS, Whiteford CC, Cenacchi N, Son CG, Khan J.
BBC3 mediates fenretinide-induced cell death in neuroblastoma.
Oncogene. 24: 7976-83, 2005.
[Journal]
28)  Son CG, Bilke S, Davis S, Greer BT, Wei JS, Whiteford CC, Chen QR, Cenacchi N, Khan J.
Database of mRNA gene expression profiles of multiple human organs.
Genome Res. 15: 443-50, 2005.
[Journal]
29)  Chen QR, Bilke S, Wei JS, Whiteford CC, Cenacchi N, Krasnoselsky AL, Greer BT, Son CG, Westermann F, Berthold F, Schwab M, Catchpoole D, Khan J.
cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
BMC Genomics. 5: 70, 2004.
[Journal]
30)  Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, Whiteford CC, Bilke S, Krasnoselsky AL, Cenacchi N, Catchpoole D, Berthold F, Schwab M, Khan J.
Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma.
Cancer Res. 64: 6883-91, 2004.
[Journal]
31)  Williams RD, Hing SN, Greer BT, Whiteford CC, Wei JS, Natrajan R, Kelsey A, Rogers S, Campbell C, Pritchard-Jones K, Khan J.
Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines.
Genes Chromosomes Cancer. 41: 65-79, 2004.
[Journal]
32)  Khan J, Wei JS, Ringnér M, Saal LH, Ladanyi M, Westermann F, Berthold F, Schwab M, Antonescu CR, Peterson C, Meltzer PS.
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks.
Nat. Med. 7: 673-9, 2001.
[Journal]
33)  Lu J, Landerholm TE, Wei JS, Dong XR, Wu SP, Liu X, Nagata K, Inagaki M, Majesky MW.
Coronary smooth muscle differentiation from proepicardial cells requires rhoA-mediated actin reorganization and p160 rho-kinase activity.
Dev. Biol. 240: 404-18, 2001.
[Journal]
34)  Mariani L, Beaudry C, McDonough WS, Hoelzinger DB, Demuth T, Ross KR, Berens T, Coons SW, Watts G, Trent JM, Wei JS, Giese A, Berens ME.
Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: a cDNA microarray analysis.
J. Neurooncol. 53: 161-76, 2001.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 4/16/2014.